Type 2 Diabetes

The phase 3 trial was stopped following a formal interim assessment that met pre specified criteria for positive efficacy in patients with chronic kidney disease.

Data from the PROMISE study provide clinicians with comprehensive insight into the safety and accuracy of the 180-day CGM system from Eversense in patients with diabetes.

Data show LNCSBs as a substitute for sugar-sweetened beverages were associated with reduced body weight, BMI, percentage of body fat, and intrahepatocellular lipid.

More studies need to be done examining the associations of increased weight and outcomes among patients with cystic fibrosis.

Funded by the ADA and ADCES, the 2022 National Standards for Diabetes Self-Management Education and Support are aimed at and were released in Diabetes Spectrum on March 9.

Results of a noninferiority trial comparing closed-loop delivery versus delivery via an open-loop system suggest use of a closed-loop system was noninferior for pediatric patients aged 6-12 years with type 1 diabetes.

A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.

Pregnant women who experienced only spontaneous abortion or both spontaneous and induced abortion were at higher risk of developing gestational diabetes.

A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.

Lifestyle interventions had no statistically significant difference in reducing worsening glycemic status compared to usual care in women with gestational diabetes.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

An analysis of data from more than 100k pregnant women suggests a history of spontaneous abortion was associated with an 18% increase in risk of subsequent gestational diabetes, with a history of multiple spontaneous abortions associated with an even greater risk.

Dr. Serge Jabbour led the panel in discussing emerging treatments for type 2 diabetes.

A population-based cohort study with data from 1.9 million patients from South Korean suggests a diagnosis of NAFLD was associated with an increased risk of severe hypoglycemic events among patients with type 2 diabetes.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

From a couple of novel heart failure treatments to a promising dual receptor agonist, here's a rundown of expected pipeline news this year in heart disease.

Multiple organizations, including the American Diabetes Association and the Endocrine Society, have released statements backing President Biden's call for insulin co-pay caps during his State of the Union Address on March 1.

Announced on March 1, the Breakthrough Device Designation from the FDA allows for use of Dexcom CGM technology in in-hospital settings and at other healthcare facilities.

General progress has been made in decreasing diabetes mortality at ages younger than 25 years, but challenges remain in low and low-middle SDI countries.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

A retrospective review with nearly a year of follow-up indicates nearly 40% of newly diagnosed diabetes at COVID-19 admission regressed to prediabetes or normoglycemia at follow-up, suggesting stress hyperglycemia induced by COVID-19-related acute stress could be driving rates of diagnosis.

A meta-analysis of studies assessing presence of pathological eating behaviors and risk of diabetic retinopathy was associated with a more than 3-fold increase in risk of retinopathy.

Obesity was added to the list of risk factors for influenza in 2009.

The latest case report from Brady Pregerson, MD, features a man in his 60s with a history of diabetes and cirrhosis presenting with 2 weeks of right upper quadrant pain with constipation and 2 days of vomiting. Can you determine the correct diagnosis?